- Report
- May 2025
- 196 Pages
Global
From €5338EUR$5,850USD£4,536GBP
- Report
- May 2025
- 657 Pages
Global
From €5338EUR$5,850USD£4,536GBP
- Report
- May 2025
- 427 Pages
Global
From €5338EUR$5,850USD£4,536GBP
- Report
- May 2025
- 293 Pages
Global
From €5338EUR$5,850USD£4,536GBP
- Report
- February 2025
- 145 Pages
Global
From €2737EUR$2,999USD£2,325GBP
- Report
- February 2025
- 144 Pages
Global
From €2737EUR$2,999USD£2,325GBP
- Report
- January 2025
- 125 Pages
Global
From €2737EUR$2,999USD£2,325GBP
- Report
- August 2024
- 136 Pages
Global
From €2737EUR$2,999USD£2,325GBP
- Report
- May 2024
- 170 Pages
Global
From €2281EUR$2,500USD£1,938GBP
- Report
- March 2025
- 200 Pages
Global
From €4097EUR$4,490USD£3,481GBP
- Report
- February 2025
- 200 Pages
Global
From €4097EUR$4,490USD£3,481GBP
- Report
- January 2025
- 175 Pages
Global
From €4097EUR$4,490USD£3,481GBP
- Report
- April 2025
- 185 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Report
- April 2025
- 182 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Report
- March 2025
- 182 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Report
- March 2025
- 182 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Report
- March 2025
- 184 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Report
- February 2025
- 185 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Report
- February 2025
- 187 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Report
- February 2025
- 184 Pages
Global
From €4106EUR$4,500USD£3,489GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more